Form 4: TG Therapeutics CFO Sells Shares to Cover Tax Obligations After Stock Vesting

TG Therapeutics CFO, Sean A. Power, sold a total of 21,358 shares of common stock to cover tax obligations following the vesting of restricted stock.

Summary

• Sean A. Power, the CFO of TG Therapeutics, sold 11,337 shares of common stock on January 3, 2025, at a price of $30.294 per share.
• He then sold an additional 10,021 shares on January 6, 2025, at a price of $28.534 per share.
• These sales were automatically executed by the company's restricted stock administrator to cover Mr. Power's tax withholding obligations related to the vesting of 45,000 shares on January 1, 2025.
• After these transactions, Mr. Power beneficially owns 660,611 shares of common stock, which includes restricted stock that vests over time.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction related to executive compensation and tax obligations. It is neither positive nor negative for the company's outlook.

Industry Context

This is a routine transaction related to executive compensation and tax obligations, common in publicly traded companies. It does not indicate any change in the company's outlook or performance.

Comparison to Industry Standards

• Sales of shares by executives to cover tax obligations upon vesting of restricted stock are a common practice across the industry.
• The number of shares sold is proportional to the tax liability incurred from the vesting of the restricted stock.
• The price at which the shares were sold is consistent with the market price at the time of the transactions.

Stakeholder Impact

• The stock sales may have a minor impact on the share price due to the increased supply of shares in the market, but this is likely to be minimal given the relatively small number of shares sold compared to the total outstanding shares.

Key Dates

Keywords

TG Therapeutics, TGTX, Sean A. Power, CFO, stock sale, restricted stock, tax obligations, insider trading, Form 4